RxDoctor Payments Data

Mamta Patel, PA

Medical · Midlothian, TXNPI 1891941175

Payments from drug & device makers

$2,267in general payments, 2019–2025

Across 26 payments — averaging $87.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • Dexcom, Inc.$420
  • Paratek Pharmaceuticals, Inc.$165
  • AstraZeneca$132
  • Sanofi$121
  • Pfizer$107
  • plus $184 from 3 others

What the payments were for

  • Consulting fees$1507%
  • Food & beverage$2,11793%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen12$1,139
Dexcom, Inc.5$420
Paratek Pharmaceuticals, Inc.2$165
AstraZeneca1$132
Sanofi1$121
Pfizer2$107
AbbVie1$103
Lilly USA, LLC1$70
GSK1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,267 in reported general payments places this provider in the 70th percentile of 1,490 medical providers in Texas.

See all medical providers in Texas

Medicare billing

Part B allowed, 2024
$22,490
Medicare patients
87
Services billed
327

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide21$23,263
JardianceEmpagliflozin15$22,160
Atorvastatin Calcium73$738
Omeprazole41$465
Gabapentin15$443
Verapamil SrVerapamil Hcl11$417
Bupropion XlBupropion Hcl19$387
Rosuvastatin Calcium27$370
Losartan Potassium32$342
Levothyroxine Sodium30$334
Famotidine26$271
Azelastine Hcl17$236
Amlodipine Besylate44$228
Fluticasone Propionate21$220
Lisinopril38$200

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$70$23,26321 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,490 medical providers in Texas.

Other medical in Midlothian

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →